LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "trial pembrolizumab" as a keyword



Abstract CT282: KEYNOTE-975: A randomized, double-blind, placebo-controlled phase 3 trial of pembrolizumab vs placebo in participants with esophageal carcinoma receiving concurrent definitive chemoradiotherapy

Sign Up to like & get
recommendations! Published in 2020 at "Cancer Research"

DOI: 10.1158/1538-7445.am2020-ct282

Abstract: Background: For patients with unresectable esophageal cancer (EC), definitive chemoradiotherapy (dCRT) is a standard treatment option. Platinum plus fluoropyrimidine-based regimens are comparable in dCRT and are considered standard options; however, overall survival (OS) is still… read more here.

Keywords: 975 randomized; keynote 975; definitive chemoradiotherapy; pembrolizumab ... See more keywords
Photo by sharonmccutcheon from unsplash

Phase II trial of pembrolizumab in patients (pts) with incurable platinum refractory germ cell tumors (GCT).

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.15_suppl.4520

Abstract: 4520Background: Despite remarkable results with salvage standard-dose (SDCT) or high-dose chemotherapy (HDCT), about 15% of pts with relapsed GCT are incurable. Immune therapy with Pembrolizumab is a novel approach for salvage in pts with metastatic… read more here.

Keywords: pembrolizumab patients; gct; trial pembrolizumab; phase trial ... See more keywords
Photo by nci from unsplash

Phase 3 KEYNOTE-361 trial: Pembrolizumab (pembro) with or without chemotherapy versus chemotherapy alone in advanced urothelial cancer.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2017.35.15_suppl.tps4590

Abstract: TPS4590Background: Only 5%-15% of patients (pts) with advanced bladder cancer attain long-term survival with standard first-line cisplatin-based chemotherapy. Programmed death 1 (PD-1)/PD-L1 inhibi... read more here.

Keywords: chemotherapy; 361 trial; keynote 361; cancer ... See more keywords
Photo by nci from unsplash

Phase 2 trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Clinical outcomes and biomarker analyses.

Sign Up to like & get
recommendations! Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.15_suppl.4087

Abstract: 4087Background: The efficacy of immune checkpoint inhibition (CPI) has not been established in ABC. The combination of CPI plus the myeloid cytokine GM-CSF was safe with prolonged overall survival ... read more here.

Keywords: plus granulocyte; pem plus; csf; pembrolizumab pem ... See more keywords
Photo by nci from unsplash

Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).

Sign Up to like & get
recommendations! Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.15_suppl.9514

Abstract: 9514Background: Immunotherapy with anti-PD-1 + CTLA-4 Abs improves response rates over anti-PD-1 Ab alone; however, the utility of this combination after first line anti-PD-1 is unknown. We report ... read more here.

Keywords: pembrolizumab pembro; plus ipilimumab; pembro plus; ipilimumab ipi ... See more keywords
Photo by nci from unsplash

Phase II trial of pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC).

Sign Up to like & get
recommendations! Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.4_suppl.386

Abstract: 386Background: The efficacy of immune checkpoint inhibition (CPI) has not been established in ABC. GM-CSF modulates immune effector cells and has demonstrated safety and improved survival (OS) in c... read more here.

Keywords: plus granulocyte; pem plus; pembrolizumab pem; trial pembrolizumab ... See more keywords
Photo by nci from unsplash

Phase Ib trial of pembrolizumab and XL888 in patients with advanced gastrointestinal malignancies.

Sign Up to like & get
recommendations! Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.4_suppl.tps526

Abstract: TPS526Background: Heat shock protein 90 (HSP90) has a central role in modulating tumor microenvironment, inflammatory signaling pathways (NF-κB, HIF-1α and Jak-STAT), tumor antigen presentation and... read more here.

Keywords: advanced gastrointestinal; xl888 patients; pembrolizumab xl888; patients advanced ... See more keywords